Headinvest LLC Purchases 410 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Headinvest LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 16.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,868 shares of the pharmaceutical company’s stock after acquiring an additional 410 shares during the quarter. Headinvest LLC’s holdings in Vertex Pharmaceuticals were worth $1,334,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of VRTX. Northwest Investment Counselors LLC bought a new position in Vertex Pharmaceuticals in the third quarter worth $25,000. Highline Wealth Partners LLC bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at $27,000. Dunhill Financial LLC raised its stake in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares in the last quarter. GHP Investment Advisors Inc. bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $29,000. Finally, Stephens Consulting LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $31,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $462.10 on Friday. Vertex Pharmaceuticals Incorporated has a 12 month low of $348.46 and a 12 month high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $472.83 and a 200 day moving average price of $475.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter in the previous year, the company earned $3.67 EPS. Vertex Pharmaceuticals’s revenue was up 11.6% on a year-over-year basis. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Analyst Ratings Changes

VRTX has been the subject of several recent research reports. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Canaccord Genuity Group increased their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a report on Wednesday, November 6th. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Scotiabank increased their price objective on Vertex Pharmaceuticals from $480.00 to $486.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Finally, UBS Group lifted their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $504.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.